CA2078545A1 - Hiv envelope polypeptides - Google Patents

Hiv envelope polypeptides

Info

Publication number
CA2078545A1
CA2078545A1 CA002078545A CA2078545A CA2078545A1 CA 2078545 A1 CA2078545 A1 CA 2078545A1 CA 002078545 A CA002078545 A CA 002078545A CA 2078545 A CA2078545 A CA 2078545A CA 2078545 A1 CA2078545 A1 CA 2078545A1
Authority
CA
Canada
Prior art keywords
residues
amino acid
antibody
thr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002078545A
Other languages
English (en)
French (fr)
Inventor
Timothy J. Gregory
Cordelia K. Leonard
Michael W. Spellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2078545A1 publication Critical patent/CA2078545A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002078545A 1990-04-03 1991-04-01 Hiv envelope polypeptides Abandoned CA2078545A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50477290A 1990-04-03 1990-04-03
US07/504,772 1990-04-03

Publications (1)

Publication Number Publication Date
CA2078545A1 true CA2078545A1 (en) 1991-10-04

Family

ID=24007676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002078545A Abandoned CA2078545A1 (en) 1990-04-03 1991-04-01 Hiv envelope polypeptides

Country Status (5)

Country Link
EP (1) EP0527789A1 (ja)
JP (1) JPH05506221A (ja)
AU (1) AU7676891A (ja)
CA (1) CA2078545A1 (ja)
WO (1) WO1991015512A2 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194836T3 (es) * 1990-09-27 2003-12-01 Tripep Ab Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
DK0601108T3 (da) * 1991-08-29 2000-04-17 Us Gov Health & Human Serv Multideterminante peptidantigener, som stimulerer T-hjælpelymfocytrespons til HIV hos en gruppe mennesker
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
CA2164505A1 (en) * 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
GB9615533D0 (en) * 1996-07-24 1996-09-04 Peptide Therapeutics Ltd Diagnostic test for herpes simplex virus type-2
ATE355300T1 (de) * 1996-11-06 2006-03-15 Genentech Inc Gespannte, helixformende peptide und verfahren um sie herzustellen
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
PT1141315E (pt) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2011008863A2 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151638T1 (de) * 1987-02-20 1997-05-15 Genentech Inc Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
AU2914889A (en) * 1987-08-28 1989-04-17 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
SE8704185L (sv) * 1987-10-28 1989-04-29 Ferring Ab Nya peptider, artificiella antigener och immunoanalystestsatser
WO1989005821A1 (en) * 1987-12-21 1989-06-29 Arch Development Corporation Hiv-related antigens and antibodies
IL88963A (en) * 1988-01-27 1996-05-14 Iaf Biochem Int Circular synthetic peptides and their mixtures for the detection of VIH antibodies and for the formation of vaccines
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines

Also Published As

Publication number Publication date
EP0527789A1 (en) 1993-02-24
JPH05506221A (ja) 1993-09-16
WO1991015512A3 (en) 1991-12-12
WO1991015512A2 (en) 1991-10-17
AU7676891A (en) 1991-10-30

Similar Documents

Publication Publication Date Title
AU647108B2 (en) Methods and compositions for vaccination against HIV
US6815201B2 (en) HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
ES2121733T5 (es) Variantes de adhesiones, acido nucleico que las codifica asi como composiciones que las contienen.
US6335017B1 (en) Compositions and methods for treating viral infections
EP0279688B1 (en) Methods and compositions for the use of HIV env polypeptides and antibodies thereto
EP0693937B1 (en) Hiv-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US7041293B1 (en) HIV env antibodies
US5614612A (en) Purified gp120 compositions retaining natural conformation
CA2078545A1 (en) Hiv envelope polypeptides
Berman et al. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160
PL155084B1 (en) A method of monoclonic antibodies generating and the useof theses antibodies in distributions based on immulogical affinity
EP1016671A2 (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
AP502A (en) Multiple branch peptide constructions for use against HIV.
WO1998041536A1 (en) Glycosylation deficient siv and hiv envelope glycoproteins
EP1011707B1 (en) HIV-1 gp120 V1/V2 DOMAIN EPITOPES CAPABLE OF GENERATING NEUTRALIZING ANTIBODIES
JP3364181B2 (ja) ヒト免疫不全ウイルスのエンベロープポリペプチドおよびその抗体
AU2008203501A1 (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
FZDE Discontinued